GLP-1 medications

A secret shopper study revealed that telehealth sites prescribing GLP-1 medications for weight loss often operate with minimal clinical oversight, enabling fast and easy access to drugs like semaglutide and tirzepatide. The study, conducted by a Yale researcher and published in the Journal of the American Medical Association, highlights concerns about virtual care practices and the market for non-FDA-approved compounded versions due to shortages.

A Medicare pilot program expands access to GLP-1 weight-loss medications like Wegovy and Zepbound for some seniors, offering subsidies as high as $50 per month. The program, running through 2027, requires a BMI above 35 or specific weight-related conditions for eligibility, though 6 million Medicare Part D recipients who might otherwise qualify will remain excluded. Concerns persist about potential bone and muscle density loss from rapid weight loss, but medical professionals suggest exercise can mitigate risks.

Experts in Charlotte, N.C., are raising concerns about the disposal of GLP-1 injection pens as the use of weight-loss drugs like Ozempic, Wegovy, and Zepbound surges. Studies estimate roughly 12% of U.S. adults are using these medications, prompting questions about post-use waste management.

A preliminary study found that testosterone levels increase or stabilize in people taking GLP-1 medications. The research suggests a potential link between GLP-1 use and improved testosterone levels.

Starting in July, Medicare beneficiaries can access GLP-1 medications via a temporary program with a flat monthly fee. The program, set to run until 2027, faces operational uncertainties ahead of its launch.

GLP-1 weight-loss drugs may improve male fertility by enhancing testosterone levels and semen quality in obese men with low testosterone. A review of five trials found no suppression of male reproductive hormones and potential benefits for metabolic health, though more research is needed.

A new study suggests GLP-1 medications like Ozempic and Mounjaro may reduce the likelihood of violent behavior, potentially influencing broader decision-making beyond dietary choices.

A new study suggests that adults taking GLP-1 medications like Ozempic or Wegovy for weight loss are significantly reducing their physical activity, with decreases in daily steps and moderate-to-vigorous exercise. Researchers emphasize that exercise remains essential for preserving strength and long-term health when using these drugs, despite the observed decline in activity.

A study of over 111,000 women aged 45 to 80 found that those using GLP-1 medications had a 30% reduced risk of developing breast cancer.

GLP-1 medications like Ozempic are gaining popularity and significantly impacting the health landscape in the US, influencing obesity rates.

CVS will cover Lilly’s GLP-1 medications, Foundayo (a pill) and Zepbound (an injection), potentially expanding access for millions of Americans.

Users of GLP-1 medications like Ozempic and Wegovy report a side effect called 'Ozempic breath,' characterized by a fishy or sewage-like odor. While not listed in official side effects, social media discussions and anecdotal evidence suggest dehydration, gut flora imbalance, and gastric reflux may contribute. Doctors recommend hydration, probiotics, and dietary changes to mitigate the issue.

A study of nearly 28,000 people reveals genetic factors influencing the effectiveness of obesity drugs and their gastrointestinal side effects. Researchers identified specific genetic variants linked to varying responses to GLP-1 medications.